Current stage-Stage IV Posts on Medivizor
Navigation Menu

Current stage-Stage IV Posts on Medivizor

Comparing the effectiveness and safety of nivolumab plus ipilimumab with chemotherapy versus pembrolizumab plus chemotherapy as first-Line treatment for metastatic NSCLC.

Comparing the effectiveness and safety of nivolumab plus ipilimumab with chemotherapy versus pembrolizumab plus chemotherapy as first-Line treatment for metastatic NSCLC.

Posted by on Oct 17, 2021 in Lung cancer | 0 comments

In a nutshell This study compared the effectiveness and safety outcomes of nivolumab (N; Opdivo) plus ipilimumab (I; Yervoy) with chemotherapy versus pembrolizumab (Pem; Keytruda) plus chemotherapy as first-line treatment in patients with metastatic non-small cell lung cancer (NSCLC). The data showed that N-I plus chemotherapy provided similar overall...

Read More

Is osimertinib an effective treatment for EGFR-mutant advanced non-small cell lung cancer in a real-world practice?

Is osimertinib an effective treatment for EGFR-mutant advanced non-small cell lung cancer in a real-world practice?

Posted by on Oct 3, 2021 in Lung cancer | 0 comments

In a nutshell This study looked at the use of osimertinib (Tagrisso) for the treatment of EGFR-mutant advanced non-small-cell lung cancer (NSCLC) in a real-world practice. It found that osimertinib was confirmed to improve survival without cancer progressing, while the occurrence of blood clots was more common in a real-world...

Read More

Evaluating the effectiveness and safety of SOX+bevacizumab or cetuximab for the treatment of patients with advanced colorectal cancer with wild-type KRAS.

Evaluating the effectiveness and safety of SOX+bevacizumab or cetuximab for the treatment of patients with advanced colorectal cancer with wild-type KRAS.

Posted by on Sep 26, 2021 in Colorectal cancer | 0 comments

In a nutshell This study compared the effectiveness and safety of S-1 (tegafur/gimeracil/oteracil) and oxaliplatin (Eloxatin) combined with bevacizumab (Avastin) or with cetuximab (Erbitux) in patients with previously untreated advanced colorectal cancer with wild-type KRAS. This study concluded that the safety and effectiveness of...

Read More

Which combination of treatments is better for HER2 positive advanced breast cancer?

Which combination of treatments is better for HER2 positive advanced breast cancer?

Posted by on Sep 17, 2021 in Breast cancer | 0 comments

In a nutshell This study compared two treatment regimes for HER2 positive breast cancer; pyrotinib (Irene) plus vinorelbine (Navelbine), or lapatinib (Tykerb) plus capecitabine (Xeloda). It found that pyrotinib plus vinorelbine (PV) improved survival without cancer progressing compared to lapatinib plus capecitabine (LC).  Some background...

Read More

Evaluating eribulin versus other treatment options in women with advanced breast cancer.

Evaluating eribulin versus other treatment options in women with advanced breast cancer.

Posted by on Aug 29, 2021 in Breast cancer | 0 comments

In a nutshell This study compared the safety and effectiveness between eribulin (Halaven) and non-eribulin-based chemotherapy regimens in patients with advanced breast cancer (BC). The data showed that eribulin significantly improved survival outcomes with manageable side effects in these patients. Some background Advanced BC has spread...

Read More

Is surgery of metastases effective after failure of modern whole-body treatments in patients with advanced melanoma?

Is surgery of metastases effective after failure of modern whole-body treatments in patients with advanced melanoma?

Posted by on Aug 22, 2021 in Melanoma | 0 comments

In a nutshell This study looked at the use of surgery for spread disease (metastases) in patients with advanced melanoma when other whole-body treatments had failed. It found that surgical removal of metastases improved the outcomes of these patients. Some background Advanced melanoma can spread to many places in the body. It is usually...

Read More

What is the effective dose of ipilimumab combined with standard dose of pembrolizumab in patients with advanced melanoma?

What is the effective dose of ipilimumab combined with standard dose of pembrolizumab in patients with advanced melanoma?

Posted by on Aug 8, 2021 in Melanoma | 0 comments

In a nutshell The study aimed to evaluate the effectiveness and safety of combining standard-dose pembrolizumab (PEM; Keytruda) with two different doses of ipilimumab (IPI; Yervoy) in patients with advanced melanoma. The study concluded that 200 mg PEM plus 50 mg of IPI showed good effectiveness and reduced toxicity compared to 100 mg...

Read More

Evaluating the safety and effectiveness of nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced non-squamous non-small cell lung cancer.

Evaluating the safety and effectiveness of nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced non-squamous non-small cell lung cancer.

Posted by on Aug 7, 2021 in Lung cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety outcomes of nivolumab (Opdivo) in combination with carboplatin (C; Paraplatin) and paclitaxel (P; Taxol) plus bevacizumab (B; Avastin) as first-line treatment for patients with advanced non-squamous non-small cell lung cancer (NSCLC). The data showed that nivolumab plus BCP...

Read More

Evaluating the long-term outcomes of cobimetinib plus vemurafenib in patients with BRAF-mutated advanced melanoma.

Evaluating the long-term outcomes of cobimetinib plus vemurafenib in patients with BRAF-mutated advanced melanoma.

Posted by on Aug 7, 2021 in Melanoma | 0 comments

In a nutshell This study reported the long-term effectiveness and safety of the combined treatment of vemurafenib (Zelboraf) and cobimetinib (Cotellic) in patients with previously untreated BRAF-mutated advanced melanoma. The data showed that the combination was safe and effective over the long term. Some background Melanoma is an aggressive...

Read More

Is a skin rash associated with the treatment response to vemurafenib and cobimetinib in patients with advanced melanoma?

Is a skin rash associated with the treatment response to vemurafenib and cobimetinib in patients with advanced melanoma?

Posted by on Jul 31, 2021 in Melanoma | 0 comments

In a nutshell The study aimed to investigate the frequency and severity of skin rash-like symptoms known as exanthema and its relationship with treatment outcome with vemurafenib (Zelboraf) alone or vemurafenib combined with cobimetinib (Cotellic) in patients with advanced melanoma. The study showed that the appearance of exanthema within 6 weeks of...

Read More

Evaluating the effectiveness and safety of anlotinib for unresponsive metastatic colorectal cancer.

Evaluating the effectiveness and safety of anlotinib for unresponsive metastatic colorectal cancer.

Posted by on Jul 25, 2021 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of anlotinib (AL3818) for the treatment of patients with unresponsive metastatic colorectal cancer (mCRC). The data showed that anlotinib was safe and significantly improved survival without cancer progression for these patients. Some background Colorectal cancer (CRC) is one of...

Read More